Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates

Huaizhong Pan, Monika Sima, Pavla Kopečková, Kuangshi Wu, Songqi Gao, Jihua Liu, Dong Wang, Scott C. Miller, Jindřich Kopeček

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

The biodistribution and pharmacokinetics of bone-targeting N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-alendronate conjugates were evaluated following intravenous administration of radioiodinated conjugates to young healthy BALB/c mice. The synthesis of a polymerizable and cathepsin K cleavable alendronate derivative, N-methacryloylglycylglycylprolyinorleucylalendronate, enabled the preparation of HPMA copolymer-alendronate conjugates with varying composition. Using the RAFT (reversible addition-fragmentation chain transfer) polymerization technique, four conjugates with different molecular weight and alendronate content and two control HPMA copolymers (without alendronate) with different molecular weight were prepared. The results of biodistribution studies in mice demonstrated a strong binding capacity of alendronate-targeted HPMA copolymer conjugates to bone. Conjugates with low (1.5 mol%) alendronate content exhibited a similar bone deposition capacity as conjugates containing 8.5 mol % of alendronate. The molecular weight was an important factor in the biodistribution of the HPMA copolymer conjugates. More conjugate structures need to be evaluated, but the data suggest that medium molecular weights (50-100 kDa) might be effective drug carriers for bone delivery.

Original languageEnglish (US)
Pages (from-to)548-558
Number of pages11
JournalMolecular Pharmaceutics
Volume5
Issue number4
DOIs
StatePublished - Jul 1 2008

Fingerprint

Alendronate
Pharmacokinetics
Bone and Bones
Molecular Weight
Cathepsin K
Drug Carriers
N-(2-hydroxypropyl)methacrylamide
Polymerization
Intravenous Administration

Keywords

  • Alendronate
  • Biodistribution
  • Bone targeting
  • Drug delivery
  • HPMA copolymer
  • Pharmacokinetics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. / Pan, Huaizhong; Sima, Monika; Kopečková, Pavla; Wu, Kuangshi; Gao, Songqi; Liu, Jihua; Wang, Dong; Miller, Scott C.; Kopeček, Jindřich.

In: Molecular Pharmaceutics, Vol. 5, No. 4, 01.07.2008, p. 548-558.

Research output: Contribution to journalArticle

Pan, Huaizhong ; Sima, Monika ; Kopečková, Pavla ; Wu, Kuangshi ; Gao, Songqi ; Liu, Jihua ; Wang, Dong ; Miller, Scott C. ; Kopeček, Jindřich. / Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates. In: Molecular Pharmaceutics. 2008 ; Vol. 5, No. 4. pp. 548-558.
@article{0700d13c8ec5429bab491423dcada53c,
title = "Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates",
abstract = "The biodistribution and pharmacokinetics of bone-targeting N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-alendronate conjugates were evaluated following intravenous administration of radioiodinated conjugates to young healthy BALB/c mice. The synthesis of a polymerizable and cathepsin K cleavable alendronate derivative, N-methacryloylglycylglycylprolyinorleucylalendronate, enabled the preparation of HPMA copolymer-alendronate conjugates with varying composition. Using the RAFT (reversible addition-fragmentation chain transfer) polymerization technique, four conjugates with different molecular weight and alendronate content and two control HPMA copolymers (without alendronate) with different molecular weight were prepared. The results of biodistribution studies in mice demonstrated a strong binding capacity of alendronate-targeted HPMA copolymer conjugates to bone. Conjugates with low (1.5 mol{\%}) alendronate content exhibited a similar bone deposition capacity as conjugates containing 8.5 mol {\%} of alendronate. The molecular weight was an important factor in the biodistribution of the HPMA copolymer conjugates. More conjugate structures need to be evaluated, but the data suggest that medium molecular weights (50-100 kDa) might be effective drug carriers for bone delivery.",
keywords = "Alendronate, Biodistribution, Bone targeting, Drug delivery, HPMA copolymer, Pharmacokinetics",
author = "Huaizhong Pan and Monika Sima and Pavla Kopečkov{\'a} and Kuangshi Wu and Songqi Gao and Jihua Liu and Dong Wang and Miller, {Scott C.} and Jindřich Kopeček",
year = "2008",
month = "7",
day = "1",
doi = "10.1021/mp800003u",
language = "English (US)",
volume = "5",
pages = "548--558",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer-alendronate conjugates

AU - Pan, Huaizhong

AU - Sima, Monika

AU - Kopečková, Pavla

AU - Wu, Kuangshi

AU - Gao, Songqi

AU - Liu, Jihua

AU - Wang, Dong

AU - Miller, Scott C.

AU - Kopeček, Jindřich

PY - 2008/7/1

Y1 - 2008/7/1

N2 - The biodistribution and pharmacokinetics of bone-targeting N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-alendronate conjugates were evaluated following intravenous administration of radioiodinated conjugates to young healthy BALB/c mice. The synthesis of a polymerizable and cathepsin K cleavable alendronate derivative, N-methacryloylglycylglycylprolyinorleucylalendronate, enabled the preparation of HPMA copolymer-alendronate conjugates with varying composition. Using the RAFT (reversible addition-fragmentation chain transfer) polymerization technique, four conjugates with different molecular weight and alendronate content and two control HPMA copolymers (without alendronate) with different molecular weight were prepared. The results of biodistribution studies in mice demonstrated a strong binding capacity of alendronate-targeted HPMA copolymer conjugates to bone. Conjugates with low (1.5 mol%) alendronate content exhibited a similar bone deposition capacity as conjugates containing 8.5 mol % of alendronate. The molecular weight was an important factor in the biodistribution of the HPMA copolymer conjugates. More conjugate structures need to be evaluated, but the data suggest that medium molecular weights (50-100 kDa) might be effective drug carriers for bone delivery.

AB - The biodistribution and pharmacokinetics of bone-targeting N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-alendronate conjugates were evaluated following intravenous administration of radioiodinated conjugates to young healthy BALB/c mice. The synthesis of a polymerizable and cathepsin K cleavable alendronate derivative, N-methacryloylglycylglycylprolyinorleucylalendronate, enabled the preparation of HPMA copolymer-alendronate conjugates with varying composition. Using the RAFT (reversible addition-fragmentation chain transfer) polymerization technique, four conjugates with different molecular weight and alendronate content and two control HPMA copolymers (without alendronate) with different molecular weight were prepared. The results of biodistribution studies in mice demonstrated a strong binding capacity of alendronate-targeted HPMA copolymer conjugates to bone. Conjugates with low (1.5 mol%) alendronate content exhibited a similar bone deposition capacity as conjugates containing 8.5 mol % of alendronate. The molecular weight was an important factor in the biodistribution of the HPMA copolymer conjugates. More conjugate structures need to be evaluated, but the data suggest that medium molecular weights (50-100 kDa) might be effective drug carriers for bone delivery.

KW - Alendronate

KW - Biodistribution

KW - Bone targeting

KW - Drug delivery

KW - HPMA copolymer

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=51049117949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51049117949&partnerID=8YFLogxK

U2 - 10.1021/mp800003u

DO - 10.1021/mp800003u

M3 - Article

VL - 5

SP - 548

EP - 558

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 4

ER -